SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shelter Pharma shines on launching ‘FOLIMAN Folic Acid Tablets’

11 May 2026 Evaluate

Shelter Pharma is currently trading at Rs. 32.11, up by 2.10 points or 7.00% from its previous closing of Rs. 30.01 on the BSE.

The scrip opened at Rs. 31.85 and has touched a high and low of Rs. 33.45 and Rs. 31.79 respectively. So far 63000 shares were traded on the counter.

The BSE group 'M' stock of face value Rs. 10 has touched a 52 week high of Rs. 50.00 on 25-Aug-2025 and a 52 week low of Rs. 26.50 on 30-Mar-2026.

Last one week high and low of the scrip stood at Rs. 33.84 and Rs. 29.00 respectively. The current market cap of the company is Rs. 54.80 crore.

The promoters holding in the company stood at 44.99%, while non-institutions held 55.01% stake in the company.

Shelter Pharma is launching a new healthcare/nutraceutical product, namely ‘FOLIMAN Folic Acid Tablets’ (Vitamin B-9 Supplement), on May 11, 2026, as part of its business expansion and product portfolio enhancement strategy. The launch is expected to strengthen the company’s presence in the healthcare segment and contribute towards future business growth. The product is being launched in the international market, and the company may subsequently introduce the same in the domestic market in due course.

Shelter Pharma is engaged in the business of manufacturing herbal products with well-built presence in Human Pharma as well as Veterinary.

Shelter Pharma Share Price

29.88 0.68 (2.33%)
15-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1806.45
Dr. Reddys Lab 1279.25
Cipla 1381.50
Zydus Lifesciences 1087.75
Lupin 2273.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: